The accelerated drug approval introduced by the FDA in 2024 was probably made possible by growing acceptance of precision medicine and genetic screening in targeted therapies, for instance, those for non-small-cell lung cancer and pancreatic adenocarcinoma, by approving zenocutuzumab-zbco (brand name Bizengri , and for transthyretin-mediated amyloidosis causing cardiomyopathy and heart failure, by approving acoramidis (brand names Attruby and Beyonttra, The P4 medicine paradigm continues to demonstrate its value across chronic diseases, even as attention increasingly shifts toward rare disorders
As healing progresses, skin typically appears brighter, smoother, and more even in tone, with results continuing to improve over time
If your provider recommends weaning or reducing feeds If weaning becomes part of your care plan, gradual reduction is often more comfortable than stopping suddenly when that is possible
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos A, et al
